Xeris wins US patent for Intracutaneous Injection
The new technology will enable biologics that are given as aqueous injections to be reformulated into a biocompatible, non-aqueous suspensions. The suspensions can be directly injected without reconstitution
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.